Safety, Tolerability and Pharmacokinetics of Single Doses of the Trpv1 Antagonist SAF 312 in Healthy Subjects.

Trial Profile

Safety, Tolerability and Pharmacokinetics of Single Doses of the Trpv1 Antagonist SAF 312 in Healthy Subjects.

Completed
Phase of Trial: Phase I

Latest Information Update: 14 Apr 2014

At a glance

  • Drugs SAF 312 (Primary)
  • Indications Dental pain; Neurogenic bladder; Postoperative pain
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Novartis Institutes for BioMedical Research
  • Most Recent Events

    • 14 Apr 2014 New trial record
    • 22 Mar 2014 Results presented at the 115th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top